Loading page...
Loading page...
This round is closed. The next round and similar open calls are listed below. Synced from the EU Funding & Tenders Portal on 9 November 2026.
This call is closed. These open or upcoming calls fund the closest work.
Based on projects the EU funded on the same subject in this programme.
AURORADemonstrating trAnsformative solUtions to empower climate Resilience tOwards impRoved public health stAtus in the EU Boreal Region
HORIZON-MISS-2023-CLIMA-01-03 · 2024 · Official record ↗
FORCEFostering Oncology Research by Charities in Europe
HORIZON-MISS-2024-CANCER-01-04 · 2025 · Official record ↗
GLIOMATCHThe malignant Glioma immuno-oncology matchmaker: towards data-driven precision medicine using spatially resolved radio-multiomics
HORIZON-MISS-2023-CANCER-01-01 · 2024 · Official record ↗
EUonQoLQuality of Life in Oncology: measuring what matters for cancer patients and survivors in Europe
HORIZON-MISS-2021-CANCER-02-02 · 2023 · Official record ↗
PREMIO COLLABPersonalised response monitoring in oncology: co-creating clinical trials in advanced breast cancer
HORIZON-MISS-2023-CANCER-01-03 · 2024 · Official record ↗
CO-CAPTAINCANCER PREVENTION AMONG INDIVIDUALS WITH MENTAL ILL-HEALTH: CO-ADAPTING AND IMPLEMENTING PATIENT NAVIGATION FOR PRIMARY CANCER PREVENTION
HORIZON-MISS-2022-CANCER-01-01 · 2023 · Official record ↗
PIECESTOWARDS LARGE-SCALE ADAPTION AND TAILORED IMPLEMENTATION OF EVIDENCE-BASED PRIMARY CANCER PREVENTION PROGRAMMES IN EUROPE AND BEYOND
HORIZON-MISS-2022-CANCER-01-01 · 2023 · Official record ↗
EPICA-DIPGEuropean Pediatric Immunotherapy Trial with Combinatory ATMPs for DIPG
HORIZON-MISS-2025-02-CANCER-04 · 2026 · Official record ↗
Each one links to its EU funding record and the partners it works with: a starting list for building a consortium.
Proposals under this topic should aim to deliver results that are directed and tailored towards and contribute to all of the following expected outcomes:
This topic will contribute to the achievement of the EU Cancer Mission’s objective to provide better quality of life for cancer patients, their families and carers. The focus is on the development of innovative models for earlier, more precise and better integrated palliative care.
According to an EU conference on innovative palliative care for people with cancer on 8 October 2024[1], palliative care has big potential but such interventions come much too late and are often imprecise. Palliative care is needed very early after cancer diagnosis with the best possible information on patient wishes and effective communication between all involved carers. Barriers also include the insufficient workforce allocation, insufficient retention and resilience of staff, incorrect transferals between care facilities, regional inequities and higher needs for home-based care. In order to improve the access to palliative care, innovative models for earlier, more precise and more patient-centred care should be developed. These models should be built on patients’ needs and the consideration of all possible care options. They should use AI and digital remote tools to empower clinicians, and to deliver well-integrated care with optimal care predictions.
Proposals should address most of the following:
Successful proposals will be asked to join the 'Quality of Life' project cluster of the EU Cancer Mission[2]. and should include a budget for networking, attendance at meetings and joint activities[3]. The Commission will facilitate coordination of these activities.
Applicants should provide details of the clinical studies in the dedicated annex using the template provided in the submission system.
[1] RESEARCH AND INNOVATION - Innovative Palliative Care for People with Cancer Conference
[2] In order to address the objectives of the EU Cancer Mission, participants will collaborate in project clusters to leverage EU-funding, increase networking across sectors and disciplines, and establish a portfolio of Cancer Mission R&I and policy actions
[3] examples of these activities are research or research capacity, organising joint workshops, establishing best practices, joint communication or citizen engagement activities with projects funded under other clusters and pillars of Horizon Europe, or other EU programmes, as appropriate. Proposals are not required to include details of these activities, as they will be defined during the grant agreement preparation and during the life of the project.
1. Admissibility Conditions: Proposal page limit and layout
described in Annex A and Annex E of the Horizon Europe Work Programme General Annexes.
Proposal page limits and layout: described in Part B of the Application Form available in the Submission System.
2. Eligible Countries
described in Annex B of the Work Programme General Annexes.
A number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon Europe projects. See the information in the Horizon Europe Programme Guide.
3. Other Eligible Conditions
Subject to restrictions for the protection of European communication networks.
described in Annex B of the Work Programme General Annexes.
4. Financial and operational capacity and exclusion
described in Annex C of the Work Programme General Annexes.
5a. Evaluation and award: Award criteria, scoring and thresholds
are described in Annex D of the Work Programme General Annexes.
5b. Evaluation and award: Submission and evaluation processes
The thresholds for each criterion will be 4 (Excellence), 4 (Impact) and 4 (Implementation). The cumulative threshold is 12.
are described in Annex F of the Work Programme General Annexes and the Online Manual.
5c. Evaluation and award: Indicative timeline for evaluation and grant agreement
described in Annex F of the Work Programme General Annexes.
6. Legal and financial set-up of the grants
Eligible costs will take the form of a lump sum as defined in the Decision of 7 July 2021 authorising the use of lump sum contributions under the Horizon Europe Programme – the Framework Programme for Research and Innovation (2021-2027) – and in actions under the Research and Training Programme of the European Atomic Energy Community (2021-2025) [[This decision is available on the Funding and Tenders Portal, in the reference documents section for Horizon Europe, under ‘Simplified costs decisions’ or through this link: https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/guidance/ls-decision_he_en.pdf]].
The granting authority may, up to 4 years after the end of the action, object to a transfer of ownership or to the exclusive licensing of results, as set out in the specific provision of Annex 5.
described in Annex G of the Work Programme General Annexes.
described in the [specific topic of the Work Programme]
Application and evaluation forms and model grant agreement (MGA):
Application form templates — the application form specific to this call is available in the Submission System
Standard application form (HE RIA, IA)
Evaluation form templates — will be used with the necessary adaptations
Standard evaluation form (HE RIA, IA) 
Guidance
HE Programme Guide 
Model Grant Agreements (MGA)
Lump Sum MGA 
Call-specific instructions 
Detailed budget table (HE LS) 
Information on clinical studies (HE) 
Guidance: "Lump sums - what do I need to know?"
Additional documents:
HE Main Work Programme 2026-2027 – 1. General Introduction
HE Main Work Programme 2026-2027 – 12. Missions
HE Main Work Programme 2026-2027 – 15. General Annexes
HE Programme Guide
HE Framework Programme 2021/695
HE Specific Programme Decision 2021/764
EU Financial Regulation 2024/2509
Decision authorising the use of lump sum contributions under the Horizon Europe Programme
Rules for Legal Entity Validation, LEAR Appointment and Financial Capacity Assessment
EU Grants AGA — Annotated Model Grant Agreement
Funding & Tenders Portal Online Manual 
Funding & Tenders Portal Terms and Conditions 
Funding & Tenders Portal Privacy Statement
Applicants asked the EU 1 questions about this call and the EU published the answers. They clarify the call documents but do not replace them.
Yes, cachexia is within the scope of this topic given its significant impact on the quality of life of cancer patients. Both pharmacological and non-pharmacological interventions are within the scope of this topic.
Read it on the EU portal ↗Answered 5 May 2026
Confirm the current call documents and submission conditions with the funding authority.
View on EU portal ↗Source: EU Funding & Tenders Portal · synced 2026-11-09
A free account keeps your shortlist and sends deadline reminders. The EUACC connector brings this call, its FAQs, past winners and similar calls into Claude or ChatGPT, so you can check fit and draft with sources.